Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Devices & FDA·CMR Surgical

CMR Surgical's Versius Plus robot cleared for gynecology nine days after Stryker deal

The Oct. 21 clearance, K261252, adds hysterectomy and five other benign gynecologic procedures to a U.S. label that covered only gallbladder removal. Stryker agreed Oct. 12 to invest about $400 million and be its exclusive U.S. sales agent.

Charted Staff2 min read
From FDA's 510(k) database and decision summary, and company announcements published Oct. 23 and Oct. 12, 2026
Versius surgical robot arms.
Versius surgical robot arms.Courtesy of CMR Surgical

CMR Surgical's Versius Plus robot can now be marketed in the U.S. for six benign gynecologic procedures, after the Food and Drug Administration cleared the expanded indication Oct. 21. Until then, its U.S. label covered one operation: cholecystectomy, or gallbladder removal.

The Cambridge, U.K., company announced the 510(k) clearance, K261252, on Oct. 23. It arrived nine days after Stryker agreed to make a preferred equity investment of about $400 million in CMR.

Why it matters: The clearance widens the U.S. label for a robot whose sales Stryker has agreed to handle. Under an alliance announced Oct. 12, Stryker is to serve as the exclusive U.S. sales agent for CMR's Versius products, and its investment carries an exclusive option to buy the rest of the company. The indications FDA clears set the range of procedures the partners can offer U.S. hospitals.

FDA's indications for use cover patients 22 and older who are eligible for soft-tissue minimal access surgery, for cholecystectomy and now for benign total hysterectomy, oophorectomy, salpingectomy, adnexectomy, ovarian cystectomy and lysis of adhesions.

FDA received the submission April 16, two weeks before CMR announced the filing on April 29, and reviewed it as a traditional 510(k) through the general and plastic surgery panel. The device is classified as a modular electromechanical surgical system under 21 CFR 878.4964, product code SCV.

The clearance comes with a limit. CMR said it carries a contraindication against using its monopolar curved scissors in gynecologic procedures, with bipolar graspers, a monopolar hook and non-energized curved scissors recommended instead. The company said it is still developing data on the monopolar scissors for possible future submissions.

The 510(k) summary describes the clinical support as a single-center, multi-surgeon, single-arm study of 45 women. Thirty had a total hysterectomy, with or without removal of the fallopian tubes or ovaries, and 15 had one or both ovaries and tubes removed. According to the summary, all 45 procedures were completed with the Versius system without conversion to another surgical approach.

The Stryker alliance

Stryker described the deal as its way into soft-tissue robotics. "Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker's strengths in endoscopy, visualization and enabling technologies," Andy Pierce, Stryker's group president of Medsurg and Neurotechnology, said in the Oct. 12 announcement.

The investment still needs regulatory approvals and must meet customary closing conditions, the companies said. CMR will continue to lead development and sales of the Versius portfolio outside the United States. CMR, founded in 2014, describes itself as a private company backed by international shareholders.

Surgical robotics has drawn both regulatory attention and capital this fall. FDA's device center put final guidance on premarket submissions for robotically assisted surgical devices on its fiscal 2027 priority list, and MMI raised $125 million on Oct. 8 to expand sales of its Symani microsurgery robot.

What comes next

CMR said it will work with U.S. hospitals and surgeons to introduce Versius Plus into gynecologic surgery, drawing on the system's use in gynecology in international markets where those procedures are authorized. The gynecology indication is the first addition to the Versius Plus U.S. label since its cholecystectomy clearance on Dec. 16, 2025. The companies have not said when the Stryker investment is expected to close.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Devices & FDA

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.